Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine

1 Jan 2016

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) inhibitors have proven to be successful agents in inducing synthetic lethality in several malignancies. Several PARP inhibitors have reached clinical trial testing for treatment in different cancers, and, recently, Olaparib (AZD2281) has gained both United States Food and Drug Administration (USFDA) and the European Commission (EC) approval for use in BRCA-mutated advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 27642590
DOI: 10.1155/2016/2346585

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicinePMID 27642590Read ↗

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.Semantic proximity Read ↗

Current status of poly(ADP-ribose) polymerase inhibitors and future directionsSemantic proximity Read ↗

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitorsSemantic proximity Read ↗

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedsideSemantic proximity Read ↗

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP InhibitorsSemantic proximity Read ↗

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingSemantic proximity Read ↗

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) InhibitorsSemantic proximity Read ↗

Mechanism of Action of PARP InhibitorsSemantic proximity Read ↗

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read ↗

PARP inhibitors: Synthetic lethality in the clinicSemantic proximity Read ↗

Development of PARP inhibitors in oncologySemantic proximity Read ↗

A review on mechanisms of resistance to PARP inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.